-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Calliditas Therapeutics AB (Publ) (NASDAQ:CALT) Rating Lowered to D at TheStreet
Calliditas Therapeutics AB (Publ) (NASDAQ:CALT) Rating Lowered to D at TheStreet
TheStreet cut shares of Calliditas Therapeutics AB (publ) (NASDAQ:CALT – Get Rating) from a c- rating to a d rating in a research note issued to investors on Tuesday, TheStreetRatingsTable reports.
CALT has been the topic of a number of other reports. Kepler Capital Markets assumed coverage on shares of Calliditas Therapeutics AB (publ) in a research report on Thursday, June 16th. They issued a buy rating on the stock. Pareto Securities assumed coverage on shares of Calliditas Therapeutics AB (publ) in a research report on Thursday, June 2nd. They issued a buy rating on the stock.
Get Calliditas Therapeutics AB (publ) alerts:Calliditas Therapeutics AB (publ) Price Performance
Calliditas Therapeutics AB (publ) stock opened at $16.65 on Tuesday. The firm has a market cap of $492.49 million, a PE ratio of -6.69 and a beta of 1.63. Calliditas Therapeutics AB has a 52-week low of $12.55 and a 52-week high of $30.77. The company has a quick ratio of 5.32, a current ratio of 5.32 and a debt-to-equity ratio of 0.64. The company's 50 day moving average is $18.17 and its two-hundred day moving average is $17.78.
Institutional Inflows and Outflows
A hedge fund recently bought a new stake in Calliditas Therapeutics AB (publ) stock. Jane Street Group LLC acquired a new position in shares of Calliditas Therapeutics AB (publ) (NASDAQ:CALT – Get Rating) during the 1st quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 11,543 shares of the company's stock, valued at approximately $221,000. 2.94% of the stock is currently owned by hedge funds and other institutional investors.About Calliditas Therapeutics AB (publ)
(Get Rating)
Calliditas Therapeutics AB (publ), a clinical-stage biopharmaceutical company, focused on identifying, developing, and commercializing pharmaceuticals products for treatments in orphan indications with initial focus on renal and hepatic diseases. It offers Nefecon, an oral formulation of budesonide that is an immunosuppressant for the treatment of the autoimmune renal disease immunoglobulin A nephropathy.
See Also
- Get a free copy of the StockNews.com research report on Calliditas Therapeutics AB (publ) (CALT)
- MarketBeat: Week in Review 9/5 – 9/9
- Prepare For A Record-Setting Quarter For Cyber Security Stocks
- The Auto Market Is Slowly Recovering, These Stocks May Outperform
- Is DocuSign On The Verge Of A Major Reversal?
- Oil and Gas Stocks: A Safe Way to Invest in Renewable Energy
Receive News & Ratings for Calliditas Therapeutics AB (publ) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Calliditas Therapeutics AB (publ) and related companies with MarketBeat.com's FREE daily email newsletter.
TheStreet cut shares of Calliditas Therapeutics AB (publ) (NASDAQ:CALT – Get Rating) from a c- rating to a d rating in a research note issued to investors on Tuesday, TheStreetRatingsTable reports.
據The StreetRatingsTable報道,在週二發佈給投資者的一份研究報告中,華爾街將Calliditas治療公司(Publ)(納斯達克代碼:CALT-GET評級)的股票從C評級下調至D評級。
CALT has been the topic of a number of other reports. Kepler Capital Markets assumed coverage on shares of Calliditas Therapeutics AB (publ) in a research report on Thursday, June 16th. They issued a buy rating on the stock. Pareto Securities assumed coverage on shares of Calliditas Therapeutics AB (publ) in a research report on Thursday, June 2nd. They issued a buy rating on the stock.
CALT一直是其他一些報告的主題。開普勒資本市場在6月16日星期四的一份研究報告中對Calliditas Treateutics AB(Publ)的股票進行了報道。他們對這隻股票發佈了買入評級。帕累託證券在6月2日星期四的一份研究報告中承擔了對Calliditas Treateutics AB(Publ)股票的報道。他們對這隻股票發佈了買入評級。
Calliditas Therapeutics AB (publ) Price Performance
Calliditas Treateutics AB(Publ)價格表現
Calliditas Therapeutics AB (publ) stock opened at $16.65 on Tuesday. The firm has a market cap of $492.49 million, a PE ratio of -6.69 and a beta of 1.63. Calliditas Therapeutics AB has a 52-week low of $12.55 and a 52-week high of $30.77. The company has a quick ratio of 5.32, a current ratio of 5.32 and a debt-to-equity ratio of 0.64. The company's 50 day moving average is $18.17 and its two-hundred day moving average is $17.78.
週二,Calliditas Treateutics AB(Publ)的股票開盤報16.65美元。該公司市值為4.9249億美元,市盈率為-6.69,貝塔係數為1.63。Calliditas Treateutics AB的52周低點為12.55美元,52周高點為30.77美元。該公司的速動比率為5.32,流動比率為5.32,債務權益比率為0.64。該公司的50日移動均線切入位在18.17美元,200日移動均線切入位在17.78美元。
Institutional Inflows and Outflows
機構資金流入和流出
About Calliditas Therapeutics AB (publ)
關於Calliditas Treateutics AB(Publ)
(Get Rating)
(獲取評級)
Calliditas Therapeutics AB (publ), a clinical-stage biopharmaceutical company, focused on identifying, developing, and commercializing pharmaceuticals products for treatments in orphan indications with initial focus on renal and hepatic diseases. It offers Nefecon, an oral formulation of budesonide that is an immunosuppressant for the treatment of the autoimmune renal disease immunoglobulin A nephropathy.
Calliditas Treateutics AB(Publ)是一家臨牀階段的生物製藥公司,專注於識別、開發和商業化用於孤兒適應症治療的藥物產品,最初的重點是腎臟和肝臟疾病。它提供Nefecon,一種口服布地奈德製劑,是一種治療自身免疫性腎病免疫球蛋白A腎病的免疫抑制劑。
See Also
另請參閲
- Get a free copy of the StockNews.com research report on Calliditas Therapeutics AB (publ) (CALT)
- MarketBeat: Week in Review 9/5 – 9/9
- Prepare For A Record-Setting Quarter For Cyber Security Stocks
- The Auto Market Is Slowly Recovering, These Stocks May Outperform
- Is DocuSign On The Verge Of A Major Reversal?
- Oil and Gas Stocks: A Safe Way to Invest in Renewable Energy
- 免費獲取StockNews.com關於Calliditas Treateutics AB(Publ)(CALT)的研究報告
- MarketBeat:回顧一週9/5-9/9
- 為網絡安全股創紀錄的季度做準備
- 汽車市場正在緩慢復甦,這些股票可能表現優異
- DocuSign是否即將發生重大逆轉?
- 石油和天然氣股票:投資可再生能源的安全途徑
Receive News & Ratings for Calliditas Therapeutics AB (publ) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Calliditas Therapeutics AB (publ) and related companies with MarketBeat.com's FREE daily email newsletter.
接受Calliditas Treateutics AB(Publ)Daily的新聞和評級-在下面輸入您的電子郵件地址,以通過MarketBeat.com的免費每日電子郵件時事通訊接收對Calliditas Treateutics AB(Publ)和相關公司的最新新聞和分析師評級的每日簡要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧